Literature DB >> 17531173

Role of complement in antiphospholipid antibody-mediated thrombosis.

Kathleen M O'Neil1.   

Abstract

The mechanisms by which an antibody that reacts with phospholipids (universal components of mammalian membranes) causes thrombosis are not immediately obvious. The development of an animal model of antiphospholipid antibody syndrome has moved the field forward in dissecting the pathogenesis of antiphospholipid antibody syndrome and has implicated the complement system in the mechanism of disease. Understanding complement's role in promoting thrombosis will be important in designing safer, more effective approaches to the treatment of patients with antiphospholipid antibodies, and may shed light on which patients are at greatest risk for thrombosis, perhaps permitting primary prophylaxis before irreversible tissue and organ damage occur.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531173     DOI: 10.1007/s11926-007-0033-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  49 in total

1.  Complement activation by anticardiolipin antibodies.

Authors:  M B Santiago; N Gaburo; R M de Oliveira; W Cossermelli
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

2.  Antiphospholipid antibody-dependent C5b-9 formation.

Authors:  M W Stewart; W S Etches; P A Gordon
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

3.  Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.

Authors:  Silvia S Pierangeli; Guillermina Girardi; Mariano Vega-Ostertag; Xiaowei Liu; Ricardo G Espinola; Jane Salmon
Journal:  Arthritis Rheum       Date:  2005-07

4.  Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation.

Authors:  Guillermina Girardi; Patricia Redecha; Jane E Salmon
Journal:  Nat Med       Date:  2004-10-17       Impact factor: 53.440

5.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

6.  Placental pathology in systemic lupus erythematosus: a prospective study.

Authors:  M S Magid; C Kaplan; L R Sammaritano; M Peterson; M L Druzin; M D Lockshin
Journal:  Am J Obstet Gynecol       Date:  1998-07       Impact factor: 8.661

7.  Activation of complement mediates antiphospholipid antibody-induced pregnancy loss.

Authors:  J E Salmon; G Girardi; V M Holers
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Antiphospholipid antibodies and complement activation in patients with cerebral ischemia.

Authors:  W D Davis; R L Brey
Journal:  Clin Exp Rheumatol       Date:  1992 Sep-Oct       Impact factor: 4.473

9.  Blood antiphospholipid antibody levels are influenced by age, sex and HLA-B8,DR3 phenotype.

Authors:  A T Colucci; G Di Lorenzo; A Ingrassia; G Crescimanno; M A Modica; G Candore; C Caruso
Journal:  Exp Clin Immunogenet       Date:  1992

10.  Complement C3 activation is required for antiphospholipid antibody-induced fetal loss.

Authors:  V Michael Holers; Guillermina Girardi; Lian Mo; Joel M Guthridge; Hector Molina; Silvia S Pierangeli; Ricardo Espinola; Liu E Xiaowei; Dailing Mao; Christopher G Vialpando; Jane E Salmon
Journal:  J Exp Med       Date:  2002-01-21       Impact factor: 14.307

View more
  3 in total

Review 1.  Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.

Authors:  René Y McNall-Knapp
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 2.  Microthrombotic/microangiopathic manifestations of the antiphospholipid syndrome.

Authors:  Sonja Praprotnik; Dusan Ferluga; Alenka Vizjak; Anastazija Hvala; Tadej Avcin; Blaz Rozman
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

3.  Evaluation of the hypolipidemic activity of 6,7-dimethoxycoumarin on placental tissue factor mRNA expression in experimental anti-phospholipid syndrome.

Authors:  Annamalai Amarnath; Veeraval Lenin; Govindaraju Archunan
Journal:  Pharmacogn Mag       Date:  2013-07       Impact factor: 1.085

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.